| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5701456 | Journal of Thoracic Oncology | 2017 | 30 Pages |
Abstract
Ceritinib, 450 mg with food, had similar exposure and a more favorable GI safety profile than ceritinib, 750 mg in fasted patients with ALK-positive NSCLC.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Byoung Chul MD, PhD, Dong-Wan MD, PhD, Alessandra MD, Scott A. MD, FRCPC, Mark MBChB, PhD, FRACP, Gloria MD, Keunchil MD, PhD, Sang-We MD, Marwan MD, MHHM, Andrea MD, Evaristo MD, Alastair MD, PhD, Richard BS, Karen BSc, Wen PhD, Jeffrey W. BSc,